Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of Daphniyunnine D in preparation of medicines for treating chronic obstructive pulmonary disease

A technology for chronic obstructive pulmonary diseases, applied in drug combinations, respiratory diseases, etc., can solve problems such as slow progress in drug treatment research, different pathogenesis, and difficulty in obtaining satisfactory curative effects

Inactive Publication Date: 2016-02-03
ZIBO DINGLI PATENT INFORMATION CONSULTING CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no drug that can curb the progressive development of COPD, and the research progress of its drug treatment is quite slow. At present, the drug for treating asthma is often used in clinical practice to treat COPD. Because the pathogenesis of COPD is different from that of asthma, it is difficult to obtain satisfactory curative effect.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Daphniyunnine D in preparation of medicines for treating chronic obstructive pulmonary disease
  • Application of Daphniyunnine D in preparation of medicines for treating chronic obstructive pulmonary disease
  • Application of Daphniyunnine D in preparation of medicines for treating chronic obstructive pulmonary disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] Embodiment 1: the preparation of the compound DaphniyunnineD tablet involved in the present invention:

[0013] Take 20 grams of compound Daphniyunnine D, add 180 grams of conventional excipients for tablet preparation, mix well, and make 1000 tablets with a conventional tablet press machine.

Embodiment 2

[0014] Embodiment 2: the preparation of the compound DaphniyunnineD capsules involved in the present invention:

[0015] Get 20 grams of compound Daphniyunnine D, add conventional auxiliary materials for preparing capsules such as 180 grams of starch, mix well, and make 1000 capsules.

[0016] The following pharmacodynamic experiments will further illustrate its drug activity.

[0017] Methods: SPF grade female BALB / c mice, 18-20g, were randomly divided into normal control group, model control group, positive control group (terbutaline, 10mg / kg, intragastric administration), drug treatment group (DaphniyunnineD5 , 10, 20mg / kg, intragastric administration), 10 rats in each group. The mice were placed in a 4L container and smoked every day (Jinjian brand cigarettes, tar content less than 16mg), five times a week, for four consecutive weeks, administered by intragastric administration 1 hour before the daily smoke. One hour after fumigation, anesthetize with sodium phenobarbita...

experiment example 1

[0018] Experimental example 1: DaphniyunnineD inhibits the production of inflammatory mediators in bronchoalveolar lavage fluid (BALF) of COPD mice

[0019] (1) Inhibitory effect of DaphniyunnineD on TNFα production in BALF of COPD mice

[0020] The proinflammatory cytokine TNFα is an initiating factor in the pathogenesis of COPD. The level of TNFα in COPD patients is higher than that of normal people, and the cultured bronchial epithelial cells can secrete TNFα in contact with cigarette smoke. TNFα can promote neutrophil degranulation, induce mucosal cell proliferation and hypersecretion, increase the production of IL-8 in epithelial cells, increase the production of matrix metalloproteinases in macrophages, and promote airway hyperresponsiveness. The purpose of this experiment is to investigate the effect of DaphniyunnineD on the production of TNFα in the BALF of COPD mice. The results are shown in Table 1.

[0021] Table 1 Effect of DaphniyunnineD on TNFα production in BA...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a new application of Daphniyunnine D in the preparation of medicines for treating chronic obstructive pulmonary disease. The application of Daphniyunnine D in the preparation of medicines for treating chronic obstructive pulmonary disease is disclosed for the first time. As the skeleton type belongs to a brand-new skeleton type and Daphniyunnine D has an unexpectedly strong inhibitory activity to chronic obstructive pulmonary disease, there is no possibility of giving any enlightenment from other compounds, and the Daphniyunnine D has outstanding substantial characteristics and obviously has remarkable progress when used in anti-chronic obstructive pulmonary disease.

Description

technical field [0001] The present invention relates to a new application of the compound Daphniyunnine D, in particular to the application of Daphniyunnine D in the preparation of medicaments for treating chronic obstructive pulmonary disease. Background technique [0002] Chronic obstructive pulmonary disease (chronic obstructive pulmonary disease, COPD) is a common chronic disease worldwide, currently ranking fourth in the global cause of death, according to the World Health Organization forecast, by 2020, COPD will rank fifth in the incidence of global diseases , ranking third among the causes of death. [0003] COPD is a disease characterized by not fully reversible airflow limitation associated with an abnormal inflammatory response of the lungs to noxious gases or noxious particles, with chronic inflammation throughout the airways, lung parenchyma, and pulmonary vessels. The cells involved in COPD include inflammatory cells such as neutrophils, T lymphocytes, and mac...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/439A61P11/00
Inventor 田丽华
Owner ZIBO DINGLI PATENT INFORMATION CONSULTING CO LTD